Philippe F. Armand

Oncology
450 Brookline Ave
Boston, MA 02215

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 267 publications

Malignant B-cell States Orchestrate Spatially Organized Immune Ecosystems in B-cell Lymphomas.

Malignant B-cell States Orchestrate Spatially Organized Immune Ecosystems in B-cell Lymphomas.

Journal: Research square
Published: August 20, 2026

Early treatment with rasburicase and risk of kidney replacement therapy and death in adults with tumour lysis syndrome: emulated target trial.

Early treatment with rasburicase and risk of kidney replacement therapy and death in adults with tumour lysis syndrome: emulated target trial.

Journal: BMJ (Clinical research ed.)
Published: July 23, 2026

A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Journal: Clinical lymphoma, myeloma & leukemia
Published: May 26, 2026

Anti-CD47 antibody magrolimab with pembrolizumab in patients with relapsed / refractory classic Hodgkin lymphoma.

Anti-CD47 antibody magrolimab with pembrolizumab in patients with relapsed / refractory classic Hodgkin lymphoma.

Journal: Haematologica
Published: March 20, 2026

SAVE, Safe Accelerated Venetoclax Escalation: A phase Ib study of obinutuzumab plus venetoclax with daily ramp-up in CLL.

SAVE, Safe Accelerated Venetoclax Escalation: A phase Ib study of obinutuzumab plus venetoclax with daily ramp-up in CLL.

Journal: Blood advances
Published: March 11, 2026

Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology.

Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: February 11, 2026

Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin.

Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin.

Journal: Blood cancer journal
Published: February 02, 2026

A phase I/II Study of Duvelisib plus Venetoclax in Patients with Relapsed/Refractory CLL/SLL or Richter Transformation.

A phase I/II Study of Duvelisib plus Venetoclax in Patients with Relapsed/Refractory CLL/SLL or Richter Transformation.

Journal: Blood advances
Published: November 04, 2025

A phase 1/2 study of duvelisib plus venetoclax in patients with relapsed/refractory CLL/SLL or Richter transformation.

A phase 1/2 study of duvelisib plus venetoclax in patients with relapsed/refractory CLL/SLL or Richter transformation.

Journal: Blood advances
Published: November 04, 2025

Introduction to a review series on marginal zone lymphoma: reclaiming the afterthought.

Introduction to a review series on marginal zone lymphoma: reclaiming the afterthought.

Journal: Blood
Published: October 24, 2025

Impact of Novel Therapies on the Efficacy of Post-Transplantation Brentuximab Vedotin Maintenance in Hodgkin Lymphoma.

Impact of Novel Therapies on the Efficacy of Post-Transplantation Brentuximab Vedotin Maintenance in Hodgkin Lymphoma.

Journal: Blood advances
Published: October 10, 2025

Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma.

Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma.

Journal: Blood advances
Published: October 10, 2025
Showing 1-12 of 267

Last Updated: 09/26/2026